ArticleMethods in molecular biology (Clifton, N.J.)2009
Scaling-up and production of therapeutic antibodies for preclinical studies.
Article in Methods in molecular biology (Clifton, N.J.), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 7 citations in OpenAlex.
- Therapeutic Antibodies: An Overview.Methods in molecular biology (Clifton, N.J.) · 2022Article
- An antibody against the F glycoprotein inhibits Nipah and Hendra virus infections.Nature structural & molecular biology · 2019Article
- Near infrared photoimmunotherapy with an anti-mesothelin antibody.Oncotarget · 2016Article
- Targeting of bone-derived insulin-like growth factor-II by a human neutralizing antibody suppresses the growth of prostate cancer cells in a human bone environment.Clinical cancer research : an official journal of the American Association for Cancer Research · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Monoclonal antibodies are increasingly used for treatment of various diseases, mostly cancer therapy and auto-immune diseases. New chimeric, humanized, or fully-human antibodies specific to novel or already validated targets are being developed in many academic labs as well as in commercial entities. A validation of antibodies in preclinical settings is an important component of the road from discovery to clinic. Preparing sufficient amount of high-quality antibodies for preclinical studies is a challenge in some cases. This article summarizes protocols used in research laboratories, and is based on our own experience in the establishment of stable clones of CHO cells to scaling-up of tissue cultures for production of antibodies in bioreactors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.